SYNTHESIS OF RETROVIRUS-LIKE PARTICLES IN TESTICULAR TERATOCARCINOMAS NLM AIDSLINE Important note: Information in this article was accurate in 1983. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


SYNTHESIS OF RETROVIRUS-LIKE PARTICLES IN TESTICULAR TERATOCARCINOMAS

J Urol; 128(5):1055-1059 1982. Unique Identifier : AIDSLINE ICDB/83604696
Harzmann R; Lower J; Lower R; Bichler KH; Kurth R; Dept. Urology, Univ. Tubingen Medical Sch., Tubingen, W. Germany


Abstract: Two lines of evidence led to the investigation of human teratocarcinoma cells in vitro for oncogenic retroviruses: the observation by electron microscopy of retrovirus-like particles budding from the syncytial trophoblasts of human placentas, and the demonstration that teratocarcinoma patients before treatment show a high serum antibody reactivity against envelope proteins of mammalian retroviruses. In all five teratocarcinoma cell lines studied so far, retrovirus-like particles have been detected by electron microscopy. The production of these human teratocarcinoma-derived (HTD)-particles is enhanced by induction procedures known to be effective in animal virus model systems. In parallel, virus induction also increases the level of chorionic gonadotropin in the culture supernatant, demonstrating syncytial trophoblast-like cells in the heterogeneous cell population of teratocarcinomas which could be responsible for HTD-particle production. The origin of these virus-like particles endogenous or exogenous - as well as their role in the pathogenesis of teratocarcinomas is not known so far. The potential value of serum antibody reactivity in teratocarcinoma patients as a diagnostic marker is discussed. (Author abstract) (9 Refs)
Keywords: Animal Antibodies, Viral/ANALYSIS Antigens, Viral/IMMUNOLOGY Cell Line Friend Virus/IMMUNOLOGY Gonadotropins, Chorionic/BLOOD Human Leukemia, Experimental/IMMUNOLOGY Leydig Cell Tumor/BLOOD Male Radioimmunoassay Retroviridae/IMMUNOLOGY/*ISOLATION & PURIF/ULTRASTRUCTURE Sarcoma Viruses, Simian/IMMUNOLOGY Sarcoma, Experimental/IMMUNOLOGY Sertoli Cell Tumor/BLOOD Teratoma/BLOOD/*MICROBIOLOGY/ULTRASTRUCTURE Testicular Neoplasms/BLOOD/*MICROBIOLOGY/ULTRASTRUCTURE JOURNAL ARTICLE

KWDanimalantibodies,viral/analysisantigens,viral/immunologycelllinefriendvirus/immunologygonadotropins,chorionic/bloodhumanleukemia,experimental/immunologyleydigcelltumor/bloodmaleradioimmunoassayretroviridae/immunology/KWDisolation&purif/ultrastructuresarcomaviruses,simian/immunologysarcoma,experimental/immunologysertolicelltumor/bloodteratoma/blood/KWDmicrobiology/ultrastructuretesticularneoplasms/blood/KWDmicrobiology/ultrastructurejournalarticle
830330
M8330024


Copyright © 1983 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1983. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1983. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .